Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan-Reference-Cited by-同舟云学术

Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan

Published:2020-12 Issue:12 Volume:119 Page:1871-1875
ISSN:0929-6646
Container-title:Journal of the Formosan Medical Association
language:en
Short-container-title:Journal of the Formosan Medical Association

Author:

Liu Chen-Hua,Su Tung-Hung,Liu Chun-Jen,Chen Pei-Jer,Chen Ding-Shinn,Kao Jia-Horng

Funder

Abbvie

Gilead Science

Merck Sharp & Dohme

Publisher

Elsevier BV

Subject

General Medicine

Reference25 articles.

1. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study;Lancet Gastroenterol Hepatol,2017

2. Hepatitis C virus infection in Taiwan: past, present, and future;Kao;J Formos Med Assoc,2016

3. Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa;Liu;Int J Nanomed,2014

4. French ANRS CO22 Hepather cohort. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study;Carrat;Lancet,2019

5. Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: the INITIATE study;Liu;J Formos Med Assoc,2019

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan;Hepatology International;2023-01-26

2. Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan;2022-11-09

3. Prevalence of Naturally Occurring Resistance Associated Substitutions in NS3/4AProtease Inhibitors in Iranian HCV/HIV Infected Patients;Current HIV Research;2021-09

4. Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy;Journal of Viral Hepatitis;2021-06-08

5. Multiple drugs;Reactions Weekly;2021-01